Alembic Scores a Double: USFDA Okays Amlodipine-Atorvastatin Tablets

Image Source: Express Pharma

Alembic Pharmaceuticals Limited has obtained final approval from the US Food & Drug Administration (USFDA) to distribute its generic Amlodipine and Atorvastatin tablets in the US market. This approval milestone allows Alembic to further penetrate the profitable US cardiovascular and hypertension drug market, providing cost-saving substitutes for highly prescribed treatments.

About the Approval

Alembic Pharmaceuticals has been granted final USFDA approval for its generic Amlodipine and Atorvastatin tablets, indicated for high blood pressure and high cholesterol, respectively.
Approval enables Alembic to commercially produce and supply these tablets in the US, an important milestone for the company's US generics business.

Therapeutic Uses

Amlodipine: A calcium channel blocker widely used for hypertension (high blood pressure) and angina (chest pain).
Atorvastatin: A statin drug that reduces cholesterol and the risk of cardiovascular events.
The single tablet facilitates both blood pressure and cholesterol control, decreasing the risk of heart attack and stroke.

Market Significance

The US market for antihypertensive and cholesterol drugs is large, with strong demand for affordable generic versions.
Alembic's foray into this segment will increase its US revenues and enhance its position as a global pharma player selling cardiovascular drugs.

Industry Context

Other Indian pharma players, such as Lupin, Dr Reddy's, and Aurobindo Pharma, have also obtained USFDA approvals for comparable hypertension and cholesterol drugs, indicating the competitive and burgeoning nature of this therapeutic zone.
Alembic has been continually increasing its US franchise with recent approvals for other cardiovascular and antihypertensive therapies, demonstrating a strategic interest in this segment.

Company Outlook

The approval is consistent with Alembic's overall strategy to strengthen its US generics business, with a greater number of Abbreviated New Drug Application (ANDA) approvals from the USFDA in recent years.

The firm is likely to introduce the newly cleared tablets shortly, targeting a portion of the US market for combination cardiovascular treatments.

Sources: Business Standard, Economic Times